Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK520 in Relapsed/Refractory Acute Myeloid Leukemia
NCT06541444Phase 1Terminated
- Sponsor
- Base Therapeutics
- Start
- Jul 2024
- Primary completion
- Jun 2025
- Modality
- Prophylactic Vaccines, Gene Editing, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of NK-520 in acute myeloid leukemia (AML) (3 arms), sponsored by Base Therapeutics. Primary endpoints: Dose-Limiting Toxicity at 4 weeks and Complete Response Rate at 104 weeks. Started Jul 2024; status: terminated.
02
Drugs
NK-520
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06541444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06541444.